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Abstract
From a liquid biopsy, cell-free DNA (cfDNA) can provide information regarding basal tumoral genetic patterns and
changes upon treatment. In a prospective cohort of 30 diffuse large B-cell lymphomas (DLBCL), we determined the
clinical relevance of cfDNA using targeted next-generation sequencing and its correlation with PET scan imaging at
the time of diagnosis and during treatment. Using a dedicated DLBCL panel, mutations were identified at baseline for
19 cfDNAs and profiles were consistent with expected DLBCL patterns. Tumor burden-related clinical and PET scan
features (LDH, IPI, and metabolic tumor volume) were significantly correlated with the quantity of tumoral cfDNA.
Among the four patients presenting additional mutations in their cfDNAs, three had high metabolic tumor volumes,
suggesting that cfDNA more accurately reflects tumor heterogeneity than tissues biopsy itself. Mid-treatment, four
patients still had basal mutations in their cfDNAs, including three in partial response according to their Deauville
scores. Our study highlights the major interests in liquid biopsy, in particular in the context of bulky tumors where
cfDNA allows capturing the entire tumoral mutation profile. Therefore, cfDNA analysis in DLBCL represents a
complementary approach to PET scan imaging.
Introduction
The concept of liquid biopsy has been well known for
several years mainly among solid tumors, for which it has
been possible to demonstrate the presence of circulating
tumor cells, circulating tumor DNA (ctDNA) contained in
plasma cell-free circulating DNA (cfDNA), and circulat-
ing micro-RNAs1–4. In healthy subjects, cfDNA arises
from the apoptosis of nucleated cells and is found at low
levels in the blood, demonstrating that detection of
ctDNA requires highly sensitive technologies, such as
those currently available with next-generation sequencing
(NGS) approaches or digital PCR. In cancer patients, it is
known that plasma ctDNA is mainly released by apoptotic
tumor cells, but may also be released by necrotic tumor
cells or actively secreted by tumor cells5, as illustrated by
the large range of DNA fragment sizes that are detected
(from 150 base pairs to several kilobases).
The value of liquid biopsies was recently highlighted in
a few series of diffuse large B-cell lymphoma (DLBCL)
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patients but also in primary central nervous system lym-
phoma (PCNSL) cases in whom high-throughput
sequencing of a panel of target genes was performed,
demonstrating the successful detection of somatic var-
iants in both the tumors and the plasma with similar
mutational profiles6–8.
Combined immunochemotherapy and targeted thera-
pies have considerably changed the management of lym-
phomas over the past decade. Nevertheless, response to
treatment is often heterogeneous, and while some patients
will remain relapse-free after therapy, others experience
early disease progression and may develop chemo-
refractoriness due to the acquisition of tumor resistance
mechanisms and the clonal evolution of tumor cells.
Therefore, ctDNA analyses theoretically offer information
regarding potentially actionable mutations, clonal evolu-
tion, treatment response, and genetic mechanisms of
resistance.
Similar to ctDNA detection, 18F-fluoro-2-dexoxy-D-
glucose (FDG) positron-emission tomography/computed
tomography (PET/CT) is a sensitive, non-invasive tool for
DLBCL staging, and has been shown to predict ther-
apeutic response and outcomes in this setting. Interim
PET (iPET) performed after two cycles of treatment or at
mid-treatment has been considered a strong predictor of
outcomes using response criteria, such as the Deauville 5-
point scale (5-PS) or the reduction in maximum SUV
(ΔSUVmax) method9. CtDNA detection and PET/CT
imaging have been simultaneously reported in two studies
using immunoglobulin high-throughput sequencing.
These works demonstrated that detection of molecular
disease in the plasma may precede PET/CT detection of
relapse and improve specificity with similar sensitivity
compared with PET/CT10–12.
On behalf the LYSA (Lymphoma Study Association), we
recently designed and validated a set of 34 genes (termed
“Lymphopanel”) selected according to the literature and a
whole-exome sequencing study of relapsed/refractory
DLBCL patients. The Lymphopanel was informative for
96% of 215 patients enrolled in LYSA trials, highlighting the
molecular heterogeneity of subtypes and identifying somatic
mutations with therapeutic and prognostic impacts13. Its
relevance and accuracy for ctDNA was not evaluated.
The primary aim of the current study was to evaluate our
Lymphopanel as a liquid biopsy tool in a prospective cohort
of DLBCL. The secondary purposes were to determine its
modification upon treatment and to correlate baseline and
dynamic ctDNA characteristics with PET scan imaging
metrics obtained at baseline and during follow-up.
Subjects and methods
Study design and patients
Thirty DLBCL or primary mediastinal B-cell lymphoma
(PMBL) patients were enrolled prospectively. Biological
material at the time of diagnosis, including DNA and
RNA from biopsies, blood and bone marrow, was col-
lected before any treatment, as well as clinical features
(bone marrow biopsy results, stage according to the Ann
Arbor classification, and international prognostic index
(IPI) calculation) were recorded. Patients were followed
after rituximab-cyclophosphamide-doxorubicin-vincris-
tine-prednisone (R-CHOP) or R-CHOP-like che-
motherapies, and blood samples (for cfDNA extraction)
were collected at mid-treatment, end of treatment, and 1
year after end of treatment. An 18FDG-PET-TDM was
performed at the time of diagnosis and during the follow-
up (mid-treatment and end of treatment, according to
treatment strategies).
Patients provided written informed consent in accor-
dance with the Declaration of Helsinki, and the institu-
tional review board approved the protocol (Registration
clinical.gov number: NCT02339805).
Sample collection and processing
Tumor genomic DNA (gDNA) was isolated from
fresh or formalin-fixed paraffin-embedded (FFPE)
diagnostic tissue biopsies. Bone marrow samples were
collected at the time of diagnosis. From fresh tissue and
bone marrow, gDNA was extracted using proteinase K
followed by salt and ethanol precipitation and was
stored at −20 °C in 10 mM Tris-Cl and 1 mM EDTA
(pH 8) buffer. From FFPE tissue, gDNA was extracted
using the QIAamp DNA FFPE Tissue Kit (Qiagen,
Courtaboeuf, France), according to the manufacturer’s
instructions.
CtDNA monitoring was completed on serial plasma
samples. For each patient, plasma samples were collected
at baseline and interim monitoring was performed on
samples obtained at mid-treatment, at the end of treat-
ment, 6 months after the end of treatment, and in case of
relapse (Supplementary Fig. S1). Blood was collected in
EDTA tubes that were centrifuged for 10 min at 3000 rpm
within 3 h of collection. Plasma was aliquoted into 1 mL in
microtubes and stored at −80 °C until extraction. After
thawing, plasma aliquots (from 1 to 3mL) were cen-
trifuged for 5 min at 13,000 rpm. Then, cfDNA was
extracted from the supernatant using the QIAamp cir-
culating nucleic acid kit (Qiagen) and quantified using
QuBit High Sensitivity dsDNA (Thermo Fisher Scientific,
Illkirch, France).
GCB/ABC phenotyping
For tumoral samples, cell of origin (COO) molecular
classification was obtained using the Hans algorithm14.
Immunohistochemistry staining was performed for CD10,
BCL6, MUM1, MYC, BCL2, FOXP1, and IgM as descri-
bed previously15,16.
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Sequencing and copy number variations (CNV) detection
At the time of diagnosis, gDNA and cfDNA were
sequenced with the entire Lymphopanel. Ion Torrent
Personal Genome Machine (Thermo Fisher Scientific)
Sequencing was performed using our Lymphopanel as
previously described. Briefly, the Lymphopanel was
designed to identify mutations in 34 genes important for
lymphomagenesis grouped into 8 specific pathways. This
design covers 87,703 bases and generates 872 amplicons.
Variant analysis was performed using an in-house gen-
erated bioinformatics pipeline that was previously
described6,13,17. CNV detection was performed using
ONCOCNV software as previously described17,18.
Sanger sequencing was also performed to validate a
portion of the mutations found in tumoral gDNA using
the BigDye® Terminator v3.1 Cycle Sequencing Kit and an
ABI PRISM 3130 analyzer (Applied Biosystems, Forster
City, CA, USA).
During follow-up, to increase the sensitivity and for
cost-effectiveness of the sequencing, only mutated
amplicons detected at baseline were sequenced and used
to detect minimal residual disease in cfDNA.
The tumoral cfDNA (ctDNA) concentrations were
expressed in haploid genome equivalents per mL of
plasma (hGE/mL) and calculated by multiplying the
mean variant allelic frequency (VAF) by the con-
centration of cfDNA (pg/mL of plasma) and dividing by
3.3, as previously described in the publication by Scherer
et al12.
PET scan analysis
All patients underwent [18F]fluorodeoxyglucose-PET/
CT (FDG-PET/CT) before the onset of chemotherapy in
the nuclear medicine department, according to standard
procedures. The following parameters were determined
on the baseline scan: (1) SUVmax, the highest SUVmax
measured in the tumor sites and (2) total metabolic tumor
volume (MTV), which was obtained by summing the
metabolic volumes of all the nodal and extranodal lesions,
a volume of interest was set around each lesion (node or
organ involvement) as previously described19. The bone
marrow involvement was only included in the volume
measurement if there was focal uptake. The spleen was
considered as involved if there was focal uptake or diffuse
uptake higher than 150% of the liver background. Total
lesion glycolysis (TLG) was also calculated as the sum of
the product of the metabolic volume of each local tumor
based on its SUVmean (TLG= ΣMTV × SUVmean). For
segmentation, the 41% SUVmax threshold method was
used19,20. iPET was planned in all treated patients at mid-
treatment, allowing us to assess early response using the
5-point Deauville score (5-DS) and the DeltaSUV
(ΔSUVmax) calculation as previously reported21. PET was
also performed at the end of treatment and the response
was assessed according to the current recommendations
(Supplementary Fig. S1)22.
Statistical analysis
All statistical analyses were performed using R software
version 3.1.223. Progression-free survival (PFS) was eval-
uated from the date of enrollment to the date of disease
progression, relapse or death from any cause. Overall
survival (OS) was evaluated from the date of enrollment
to the date of death from any cause. Log-rank tests were
used to assess differences in the OS and PFS rates cal-
culated by Kaplan–Meier estimates. Statistical differences
between parameters in box plots were determined using
the Wilcoxon test. P-values < 0.05 were considered sta-
tistically significant.
Results
Patient population description
A prospective series of 30 consecutive untreated DLBCL
or PMBL patients were enrolled and followed after R-
CHOP or R-CHOP-like chemotherapies. Patients’ clinical
features are listed in Table 1. One patient died before
beginning any chemotherapy. From mid-treatment, 17
patients achieved complete response (Deauville score ≤ 3),
2 were stable (absence of metabolic response), and
10 showed a partial response (Deauville score > 3). At the
end of treatment, 1 more patient had died, 6 patients
presented a partial response, 4 a progression, and 18 a
complete response. At the end of the trial, 1 patient
decided to stop follow-up, 20 patients showed a complete
response, 3 relapses were observed including 1 with pre-
mature death, 2 progressive patients had died, and the 2
others still presented a progression (Supplementary Fig.
S2, Supplementary Table S2).
Plasma genotyping at baseline
To determine the clinical relevance of liquid biopsy at
the time of diagnosis, we first assessed the basal DLBCL
genetic patterns with cfDNA by targeted NGS. CfDNA
was available from the 30 patients. The mean plasma
DNA concentration was 74 ng/mL [14.6–433], and
sequencing was performed with the entire panel with a
mean depth of 3750×. cfDNA mutations were identified in
19/30 patients (63%). The mutation profiles were con-
sistent with patterns usually observed in DLBCL and
previously reported by analyzing the tumor tissues13,17
(Fig. 1).
KMT2D (MLL2) and PIM1 were the most mutated
genes, with somatic mutations in 36.7% of cases (n= 11/
30), followed by SOCS1 and TP53 in 26.7% (n= 8/30);
MYD88 and BCL2 in 23.3% (n= 7/30); GNA13 and
PRDM1 in 20% (n= 6/30); EZH2, FOXO1, and TNFAIP3
in 16.7% (n= 5/30); ITPKB, CD79B, B2M, STAT6, EP300,
and CREBBP in 13.3% (n= 4/30); CARD11, MFHAS1,
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TNFRSF14, MEF2B, CD58, and MYC in 10% (n= 3/30);
CIITA in 6.7% (n= 2/30); and IRF4, CD79A, and BRAF in
3.3% (n= 1/30). The mutation distribution was associated
with the COO subtype, such as MYD88 (particularly
L265P), PIM1, and CD79B in ABC DLBCL; EZH2, BCL2,
and GNA13 in GCB DLBCL or STAT6, SOCS1, and
MFHAS1 in PMBL. Multiple mutations were identified in
genes such as IRF4, SOCS1, PIM1, and BLC2, suggesting
an AID process as previously described13.
The cfDNA VAF was very variable with a mean of 18.2%
[0.8–87.4]. The mean concentration of ctDNA was 4604
hGE/mL [0–39,151]. A high concentration of cfDNA
signaled the presence of circulating DNA from tumoral
origins, as no plasma samples with cfDNA concentrations
above the average were negative for mutations (p= 5.6 ×
10−4, Supplementary Fig. S3).
Tumor genotyping at baseline and concordance with
plasma genotyping
When available, matched gDNA from tissue biopsies
was sequenced with the Lymphopanel and compared to
the cfDNA results. Enough material was obtained for 25
patients, including 11 frozen and 14 FFPE biopsies.
The sequencing results were interpretable for 24 cases
and not interpretable for 1 case (#28) (Fig. 1). Mutations
were found in the 24 interpretable cases; for the 6
remaining cases without workable tumoral materials, an
informative mutational pattern was successfully obtained
in 4 matched cfDNA. Finally, the mutations at baseline
were detected either in gDNA or ctDNA in 28/30 cases,
giving an informativity rate of 93%.
In five cases, additional mutations were only detected in
cfDNA compared to gDNA (#3, #5, #10, and #16). Con-
versely, some mutations found in gDNA were not found
in cfDNA, as it has been previously described6,7. In these
cases, the mutations did not necessarily have the lowest
VAF in the gDNA, showing that the mutations were not
subclonal. For paired samples, mutations were detected in
cfDNA up to a VAF of 4.6% in gDNA (patient #7). The
mean VAF was significantly higher in tumor DNA (33%)
compared to cfDNA (p= 5.6 × 10−7), but in some cases
the VAF in cfDNA was nearly similar to the VAF in
gDNA, reflecting the abundance of circulating DNA from
tumoral origins.
After sequencing the tumors, we confirmed the results
in cfDNA by performing a new sequencing method tar-
geting only the identified mutations to increase sensitivity
(Supplementary Table).
CNV analysis at baseline
CNV analysis was performed in both plasma and tumor
samples using the entire panel. As expected in DLBCL
cases, we frequently found deletions at the 6q and 9p loci
(33% and 37%, respectively) as well as TP53 deletions
(13%) in the DLBCL cases. The gains and/or losses
identified were similar in the paired samples from a
patient. Discordances were principally due to the quantity
of tumoral DNA contained in the sample from the tissue
biopsy or plasma (according to mean VAF, Supplemen-
tary Fig. S4).
Table 1 Patients characteristics
Characteristics Patients (%)
Men/women 17/13
Median age 67 [20–93]
IPI score
0–1 8 (27)
2–3 14 (46)
4–5 8 (27)
LDH > normal value 12 (40)
Stade III–IV 21 (70)
Bone marrow involvement 0/25 (0)
COO classification
Hans (Non-GCB/GCB/NA) 9 (34)/17 (66)/5
MYC + expression 7/25 (28)
BCL2 + expression 16/24 (66)
Dual expression 5/21 (24)
First-line treatment
RCHOP 16 (55)
RCHOP-like regimen (RACVBP/R miniCHOP) 13 (45)
Treatment response
CR 20
PR 5
PD 1
TEP base line features
SUV max 22.61 [4.66–43.03]
Metabolic tumor volume (MTV) 399.28 [0.29–2846]
Total lesion glycolysis (TLG) 4697.50 [1.17–31149]
Delta SUV at interim PET
>70% 22
<70% 7
Deauville score at interim PET
1–3 17
4–5 12
Deauville score at final PET
1–3 14
4–5 10
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In cfDNAs, CNVs were detectable when tumoral cir-
culating DNA was abundant; according to the mean VAF
from the seven positive patients, this was when the
tumoral circulating DNA ranged from 13 to 45% (p <
0.001, Fig. 2, Fig. S4). Above this threshold, patients
negative for CNVs in cfDNA were also negative in
Fig. 1 Basal genetic patterns in plasma cfDNA and matched tumoral DNA. Representation of the prevalence and molecular spectrum of somatic
mutations (SNVs and Indels) identified in cfDNA (upper panel) and paired tumoral DNA (lower panel) at the time of diagnosis. The 34 genes in the
Lymphopanel are grouped by pathway
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tumoral samples, except for one patient (#19). For this
particular case, the mean VAF was 14%, but with only one
mutation, while patient #29 had a mean VAF of 13.4%
calculated from 10 mutations with frequencies between 6
and 40%. Therefore, with a threshold of 13.4% for mean
VAF in the cfDNA, CNVs were detectable in 91% of the
cases (10/11). If we expressed these results based on the
quantity of ctDNA using a threshold of 1630 hGE/mL for
ctDNA, all the positive plasmas were above this value,
highlighting the importance of both the VAF and cfDNA
concentration at the time of diagnosis.
Correlation between cfDNA and clinical or TEP baseline
features
We first compared the presence of ctDNA with stan-
dard clinical indices. CfDNA mutations were observed in
all patients but one with elevated serum lactate dehy-
drogenase (LDH), but the presence of mutations was not
correlated to the disease stage. The mean VAF in cfDNA,
as well as cfDNA concentration, were significantly cor-
related with LDH and the IPI. The quantity of ctDNA
was more significantly correlated with these two features
(p= 0.001 and p= 0.02, respectively, Fig. 3a), once again
highlighting the importance of both the VAF and cfDNA
concentration at the time of diagnosis.
PET scan imaging (18F-FDG PET/CT) data were col-
lected for all the patients at baseline. The mean MTV was
743.69 cm3 (0.29–2846.62) and the mean TLG was
8341.96 (1.17–31149.00). At the time of diagnosis, both
MTV and TLG correlated strongly with the ctDNA
concentration (p < 0.001 and p= 0.002, respectively,
Fig. 3b), and more significantly than the concentration or
VAF alone, as for clinical features. Patients with an MTV
below the median (399.28 cm3) had a superior OS and
PFS compared with those with a high MTV (p= 0.016
and p= 0.009, respectively, Fig. S5).
Fig. 2 CNV analysis in plasma and tumor. a Boxplot representation of mean VAF (upper panel) or ctDNA amount (lower panel) according to the
detection of the CNVs in the plasma samples (neg= negative and pos= positive). The dashed blue lines show the thresholds of detection for CNVs
in cfDNA, corresponding to 13.4% for the mean VAF and 1630 hGE/mL for ctDNA. b Example of CNVs from patient #5 in tumor (upper panel) and
plasma (lower panel) showing the concordance of the two results when cfDNA of tumoral origin is abundant
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We calculated a heterogeneity coefficient H represent-
ing the number of mutations found in the cfDNA com-
pared to gDNA (H= (Number of mutations in gDNA
−Number of mutations in cfDNA)/Number of mutations
in gDNA). This coefficient was significantly correlated
with the MTV (p= 0.013, Fig. 4b). Three in four patients
(#5, #10, and #16) presenting additional mutations in the
cfDNA, compared to gDNA (h < 0), had a high MTV
above 2000 cm3 (Fig. 4a). The 3D view of the PET images
showed that two of these patients had many tumoral
masses (#5 and #10), as well as a fourth patient who had a
low MTV despite additional mutations in its cfDNA (#3,
Fig. 4c). These data suggest that cfDNA mutation analysis
more accurately reflects the spatial tumor heterogeneity
than tissue biopsy analysis. Conversely, the three patients
(#7, #11, and #14) with more mutations in tumor DNA
(0 < h < 1) had lower MTV values (<500 cm3). Interest-
ingly, patient #17 presented the same mutations in its
cfDNA and tumor DNA (h= 0) and an important MTV
(2375 cm3), but the mutation VAFs were high in the
Fig. 3 Correlations between tumoral cfDNA amounts and clinical/PET baseline features. CtDNA amount is significantly correlated with the
clinical indices LDH (threshold= 480 UI/L) and IPI (a), and with the PET features MTV and TLG (threshold=mean) at the time of diagnosis (b)
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plasma sample compared with the tumor sample. All the
patients with negative plasma (h= 1) had MTVs less than
800 cm3.
CfDNA monitoring and correlation with iPET and final
analysis
Longitudinal analysis of the plasma samples collected at
mid-treatment and at the end of treatment or at relapse/
progression was performed and correlated with the PET
scan characteristics (ΔSUVmax and Deauville score).
Upon treatment with R-CHOP/R-CHOP-like regimens,
a rapid clearance of cfDNA mutations was observed in the
16 baseline positive cases available at mid-treatment
(Fig. 5 and Supplementary Table S1). In four cases (#5,
#19, #25, and #29), the basal DLBCL mutations did not
completely disappear at mid-treatment. Among these four
patients, three had a delta VAF (ΔVAF) less than 90% and
were in partial response according to their Deauville
Scores (#19, #25, and #29), including two with a ΔSUV-
max <70% (#19 and #29). Patient (#25) had a ΔSUVmax of
75%, though the ΔVAF was 81% and ctDNA was still
detectable (VAF= 1.4%). Moreover, patient #29 finally
showed progression and died before the end of treatment.
Conversely, for patient #7, the mutations disappeared
from the cfDNA at mid-treatment (ΔVAF near 100%)
despite the absence of metabolic response (Deauville
score of 5) and a ΔSUVmax <70% (−28).
Unfortunately, at the end of treatment, some important
plasma samples were missing (only 20 available). Patient
#10, who presented progressive disease, had no plasma
samples either at the end of treatment or after. Patient #25
had a partial response and circulating DNA of tumoral
origin at mid-treatment, but no plasma samples were
collected for further follow-up.
Fig. 4 Tumoral heterogeneity. a Metabolic tumor volume according to the coefficient of heterogeneity (H= (Number of mutations in tumor DNA
−Number of mutations in cfDNA)/Number of mutations in tumor DNA). The red dots represent the patients with more mutations detected in the
cfDNA than in the tumoral DNA (H < 0). b Boxplot representation of the MTV values according to the presence (red dots, H < 0) or absence (blue dots,
H ≥ 0) of supplementary mutations in the cfDNA. c 3D view of PET scan images for the four patients presenting supplementary mutations in the
cfDNA, with MTV in orange boxes and TLG in green boxes
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Patients’ examples
As an example, two emblematic patients were more
extensively described (Fig. 6).
Patient #5 had one of the highest MTVs in its baseline
PET scan (2441 cm3), with an important dissemination of
the tumoral mass showed by the 3D view of the PET
images (Figs. 4c, 6a). The plasma sample was very rich in
tumoral cfDNA according to the important VAF values,
which had a mean of 44.4% (ctDNA amount of
22,508 hGE/mL), and the CNV analysis showed the same
gains and deletions in the plasma and tumor (Fig. 2b).
More mutations were observed in the cfDNA compared
with tumoral DNA (Fig. 4 and Supplementary Table S1),
indicating spatial tumor heterogeneity that was probably
correlated with the dissemination observed in the PET
images. At mid-treatment, this patient showed a complete
response with a Deauville score of 3 and a ΔSUVmax of
92%. The ΔVAF was 97%, but we still detected tumoral
DNA circulating in the plasma with a mean mutation
VAF of 1.5%. At the end of treatment and 6 months post
treatment, this patient had yet a complete response and
no more tumoral circulating DNA was found. Despite an
unfavorable somatic mutation profile, including MYD88
mutations and a CDKN2A deletion, the patient is still
considered in CR after 2 years of follow-up.
Patient #19 had a TP53 mutation detected both in its
cfDNA (VAF= 14%) and tumoral gDNA (Supplementary
Table S1). The plasma sample was informative despite the
low MTV (128 cm3). This mutation was still present in the
cfDNA at mid-treatment, but with a decreased VAF (4.3%,
Fig. 5 Longitudinal assessment of mutation abundance in plasma cfDNA upon R-CHOP treatment according to interim PET scan.
a Distribution of the cfDNA mean VAFs of the patients at the different times of follow-up (diagnosis, mid-treatment, end of treatment, and 6 months
post-treatment). b Evolution of the cfDNA mean VAFs for each patient throughout treatment. c ΔVAF values in plasma according to the ΔSUVmax
(left) or Deauville score (right) between diagnosis and mid-treatment. The vertical dashed lines represent the cut-off ΔSUVmax of 70% (left) or
Deauville score of 3 (right), and the blue dots represent patients with ΔVAF <90%
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Fig. 6 Examples of non-invasive real-time monitoring of the DLBCL clonal evolution in plasma cfDNA. Mean VAF and PET scan images at
different times during follow-up for patient #5 (a) and patient #19 (b)
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ΔVAF= 75%), though the patient was partially respond-
ing to treatment with a ΔSUVmax of 35% and a Deauville
score of 5. Of note, even if we observed a decrease in the
TP53 mutation frequency, the ΔVAF of 75% was the
lowest ΔVAF in the cohort. At the end of treatment, the
patient was still in partial response according to the PET
scan images and still harbored tumoral cfDNA, as shown
by a persistent detectable TP53 mutation with a VAF of
5% (Fig. 6b). Four months after the end of treatment, the
patient had progressive disease and the frequency of the
TP53 mutation increased to 10.7%. Five months later,
treatment by radiotherapy led to an improvement
according to PET scan data, though the two following
PET scans showed progression and a stable persistent
hypermetabolism that was not specific. Finally, we ana-
lyzed an extra plasma sample (nearly 2 years after the end
of treatment) and observed that the same TP53 mutation
was still present at a VAF of 7.16%, supporting the better
sensitivity of the liquid biopsy.
Discussion
In this prospective study we assessed basal DLBCL
genetic patterns, their modification upon treatment using
plasma cfDNA analysis, and their correlation with PET
scan imaging by NGS. In complement with previously
published results obtained from tumor biopsies from
patients enrolled in LYSA clinical trials, we demonstrated
here that the 34-gene Lymphopanel (87,703 bp) is also a
reliable genotyping tool to characterize tumoral cfDNA in
plasma13,17. CfDNA mutations were identified in 19/30
patients (63%) cases, a similar rate to that reported by
Rossi et al.7 in the training cohort (2/30, 66%). In the
validation cohort, 17/20 (85%) DLBCL patients harbored
cfDNA mutations, a higher rate that can be explained by
another distinct technology (CAPP-Seq) and a larger gene
panel (59 genes, 207,299 bp). However, despite the
quantitative and qualitative differences of the interrogated
genes, CAPP-Seq and the Lymphopanel-Ampliseq-based
technologies allowed the recovery of at least one clonal
mutation in 92.6 and 96% of DLBCL patients, respectively,
as documented by in silico validation or cohort sequen-
cing7,13. This suggests that the discrepancy observed
between the two studies is most likely related to the
higher sensitivity of the CAPP-Seq method. Nevertheless,
we identified mutations in cfDNA up to a VAF of 4.6% in
gDNA, while in the Rossi et al. study the cut-off for
detection was 20%. Of note, we also recently tested our
Lymphopanel-Ampliseq approach in PCNSL and showed
that it represents a reliable genotyping tool in a setting
where tumor cfDNA amounts are supposed to be low and
inconstant8. For these reasons, we are currently develop-
ing new approaches of sequencing, as an alternative of
CAPP-Seq, to date not widely implemented in routine,
using our lymphopanel with molecular barecoding and
dedicated bio informatic tools in order to improve
sensitivity.
The 34-gene Lymphopanel has been extensively per-
formed in more than 300 DLBCL cases17 and was initially
design to discriminate the three main molecular subtypes,
namely, the GCB, ABC, and PMBL subtypes and to pro-
vide markers for personalized medicine and targeted
treatment. The results obtained by cfDNA genotyping are
consistent with the patterns usually observed in the dif-
ferent subtypes and confirm the clinical relevance of the
panel to detect targetable variants such as EZH2, CD79B,
or MYD88 hotspot mutations. Of note, three among the
four PMBL cases were informative in both tumor and
plasma and displayed a typical genotype, suggesting that
cfDNA is likely a promising tool for the management of
PMBL.
Importantly, we were also able to detect CNVs that
accurately and specifically matched with gDNA in some
cases (Fig. 2), including the unfavorable prognostic dele-
tion of TP53 or CDKN2A. However, in our hands and
with the AmpliSeq Technology, CNVs were detectable in
cfDNA in a limited number of cases, with a minimal mean
VAF of 13% or 1630 hGE/mL ctDNA.
Factors that influence the amount of tumor cfDNA are
partially known. Here, we confirmed previous works
showing that baseline cfDNA amounts strongly correlate
with tumor burden indicators including LDH level and
the IPI score but also MTV or TLG12. Moreover, the
patients presenting additional mutations in cfDNA,
compared to gDNA, had a high MTV, suggesting that
cfDNA mutations more accurately reflect tumor hetero-
geneity than gDNA analysis, which is limited by the
unique biopsy site. Regarding the well-established prog-
nostic value of the MTV in DLBCL, cfDNA amounts may
explain the strong prognostic values recently reported in
DLBCL12,24. In addition to the combined analysis of the
MTV and GCB/ABC status or BCL2/MYC expression25,
it appears relevant to obtain both cfDNA and MTV at
baseline to risk stratify newly diagnosed DLBCL.
We performed longitudinal analysis of plasma samples
collected at mid-treatment, at the end of treatment, or at
relapse/progression and correlated the results with PET
scan characteristics. A rapid decrease in the cfDNA
mutation VAF was observed in most cases. Rapid clear-
ance of ctDNA after two cycles of R-CHOP, higher than 2
log, has been recently reported as a strong prognostic
marker24. From mid-treatment, to increase the sequen-
cing sensitivity and for cost-effectiveness reasons, only
mutations detected at baseline were monitored during the
follow-up. Some patients with partial remission at mid-
treatment, according to their Deauville score and
ΔSUVmax (<70%), still had basal DLBCL mutations cir-
culating in the plasma. Conversely, despite the partial
response, some patients had no ctDNA in the plasma.
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Thus, the targeted approach is questionable because it
precludes any detection of new (or subclonal) variants
emerging during treatment, as it has been reported by
Rossi et al7. Regardless of the liquid biopsy value, follow-
up with the entire panel is recommended. These data also
suggest that interim iPET and cfDNA can both be used to
define early response during DLBCL treatment9. Their
respective and complementary relevance remains to be
determined in a larger cohort.
Interestingly, one elderly patient (#19) in partial
remission had progressive disease 6 months after the end
of treatment and still harbored tumoral cfDNA, as shown
by a persistent detectable pathogenic TP53 mutation.
However, the tumor volume still remains stable and,
importantly, the mutation was also detected in the bone
marrow without any evidence of invasion (according to
PET scan and bone marrow sample analysis). Persistent
variants should be analyzed with caution, especially those
targeting TP53 in elderly patients because it has been
demonstrated that blood cells from more than 2% of
individuals (5–6% of people older than 70 years) contain
mutations that may represent premalignant events that
cause clonal hematopoietic expansion26,27. Age-asso-
ciated, low-frequency TP53 mutations were also found in
100% of peripheral blood samples from 15 women with
and without ovarian cancer (none with hematological
disorder)28.
To conclude, our prospective study demonstrates that
cfDNA genotyping of DLBCL is an accurate genotyping
tool and represents a real-time and non-invasive approach
for follow-up. It highlights the major interest of liquid
biopsy in the context of bulky tumors, where cfDNAs are
more representative than gDNA for capturing the entire
tumoral mutation profile. Therefore, cfDNA analysis
represents a complementary approach to PET scan ima-
ging at baseline and during follow-up for the management
of DLBCL.
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